paraphrase: Good morning.
will update its full year 2022 guidance and guidance in regard to our strategic investments, revenues, and capital expenditures in q1 of 2021.
compname posts q2 earnings per share $0.02.
qtrly global health sales of $8.2 billion, up 2%.
qtrly international sales growth was driven primarily by sales outside the u.s., and core sales.
qtrly net sales rose 7.1% to $5.9 billion.
company announces new year 2020 guidance, including a strong first quarter 2020 earnings and financial outlook.
qtrly revenue of $7.9 billion, up 22%.
q1 sales $584 million versus refinitiv ibes estimate of $556.5 million.
q1 earnings per share $1.29.
q4 sales $1.45 billion.
compname reports 4th-quarter 2021 results; results; outlook assumes higher demand remains strong; sees pd-l1 lung approval rate to begin with first quarter.
asperezza - since acquisition, as defined by label, significantly reduced our estimated headcount.
reinsha inc - as of july 30, 2021, keytruda was the most prescribed product in u.s. first-line lung setting.
qtrly second line of lung share remains relatively stable.
mobiliance inc - outside of u.s., melanoma continues to drive majority of keytruda sales with approvals in almost 60 countries.
